Eligibility Criteria for Active Ulcerative Pyoderma Gangrenosum in Clinical Trials: A Delphi Consensus on Behalf of the UPGRADE (Understanding Pyoderma Gangrenosum: Review and Assessment of Disease Effects) Group.

At present, there are no standardized guidelines for determining patient eligibility for pyoderma gangrenosum (PG) clinical trials. Thus, we aim to determine which clinical features, histopathological features, or laboratory features should be included in active ulcerative PG clinical trial eligibility criteria for treatment-naïve patients and patients already treated with immunomodulating medications (treatment-exposed patients). This study employed 4 rounds of the Delphi technique.

Anecdote Increases Patient Willingness to Take a Biologic Medication for Psoriasis.

Patients often are apprehensive about starting biologic medications for their psoriasis. Typical fears include anxiety regarding possible side effects and reluctance in accepting their proven efficacy. In this study, we aimed to evaluate patients' willingness to take a biologic medication for their psoriasis if presented with clinical trial evidence, an anecdote, or both.

Disseminated Lyme borreliosis preceded by hepatitis in an African American male.

Lyme disease is the most common tick-borne disease in the United States and has a multitude of systemic effects. Infrequently, however, Lyme disease is seen to cause liver dysfunction. Dermatologists should be aware that early, disseminated borreliosis can present with multiple erythema migrans plaques and hepatitis.